AT361321T - Linear cyclodextrincopolymers - Google Patents

Linear cyclodextrincopolymers

Info

Publication number
AT361321T
AT361321T AT99931889T AT99931889T AT361321T AT 361321 T AT361321 T AT 361321T AT 99931889 T AT99931889 T AT 99931889T AT 99931889 T AT99931889 T AT 99931889T AT 361321 T AT361321 T AT 361321T
Authority
AT
Austria
Prior art keywords
cyclodextrincopolymers
linear
Prior art date
Application number
AT99931889T
Other languages
German (de)
Inventor
Hector Gonzalez
Suzie Sue Jean Hwang
Mark E Davis
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US9155098P priority Critical
Priority to US09/203,556 priority patent/US6509323B1/en
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Publication of AT361321T publication Critical patent/AT361321T/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
AT99931889T 1998-07-01 1999-06-25 Linear cyclodextrincopolymers AT361321T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US9155098P true 1998-07-01 1998-07-01
US09/203,556 US6509323B1 (en) 1998-07-01 1998-12-02 Linear cyclodextrin copolymers

Publications (1)

Publication Number Publication Date
AT361321T true AT361321T (en) 2007-05-15

Family

ID=26784076

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931889T AT361321T (en) 1998-07-01 1999-06-25 Linear cyclodextrincopolymers

Country Status (16)

Country Link
US (1) US6509323B1 (en)
EP (2) EP1093469B1 (en)
JP (2) JP4741729B2 (en)
CN (1) CN100365024C (en)
AT (1) AT361321T (en)
AU (1) AU763114C (en)
BR (1) BR9911754B1 (en)
CA (1) CA2336390C (en)
DE (1) DE69935982T2 (en)
DK (2) DK1764112T3 (en)
ES (2) ES2285844T3 (en)
HU (1) HU229473B1 (en)
IL (2) IL140552D0 (en)
MX (1) MXPA01000206A (en)
PT (1) PT1093469E (en)
WO (1) WO2000001734A1 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
CA2353552A1 (en) * 1998-12-04 2000-06-15 California Institute Of Technology Supramolecular complexes containing therapeutic agents
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1275404A1 (en) * 2001-07-11 2003-01-15 SCA Hygiene Products AB Odour regulation in hygiene products
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
JP2005527639A (en) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Methods and compositions for therapeutic use of RNA interference
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
TW515107B (en) * 2001-12-25 2002-12-21 Solidlite Corp Power-saving light-emitting diode lamp
AU2003239121A1 (en) * 2002-02-22 2003-09-09 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
FR2842106B1 (en) * 2002-07-11 2006-07-14 Centre Nat Rech Scient Aqueous dispersions of nanometric or micrometric particles for the encapsulation of chemical compounds
BR122012021252B1 (en) 2002-08-06 2018-07-10 Cerulean Pharma Inc. Cyclodextrin based polymers for supplying therapeutic agents connected to them by covalence
CA2818071C (en) 2002-09-06 2015-08-18 Cerulean Pharma Inc. Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery
RU2005114007A (en) * 2002-10-09 2005-10-10 Инсерт Терапьютикс, Инк. (Us) Materials based on cyclodextrins, their compositions and application
CN1747738B (en) * 2002-10-29 2010-11-24 川塞夫有限公司 Sustained release of antifectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
DK2216407T3 (en) 2003-03-07 2016-03-29 Alnylam Pharmaceuticals Inc therapeutic compositions
EP1625138A4 (en) 2003-04-17 2010-06-23 Alnylam Pharmaceuticals Inc Protected monomers
CA2522637C (en) 2003-04-17 2014-01-21 Alnylam Pharmaceuticals, Inc. Modified irna agents
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US20070179100A1 (en) * 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP1635763B1 (en) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US8372966B2 (en) 2003-12-19 2013-02-12 University Of Cincinnati Oligonucleotide decoys and methods of use
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
JP2007517068A (en) 2003-12-31 2007-06-28 サイデックス・インコーポレイテッド Inhalation formulations containing sulfoalkyl ether cyclodextrins and corticosteroids prepared from unit dose suspensions
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
DK1725660T3 (en) 2004-03-05 2011-08-29 Benitec Inc Expression cassettes with multiple promoters for simultaneous delivery of RNAi agents
EP1730751B1 (en) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CA2593509A1 (en) * 2005-01-06 2006-07-13 Benitec, Inc. Rnai agents for maintenance of stem cells
AU2006210443B2 (en) 2005-02-03 2011-01-27 Benitec, Inc. RNAi expression constructs
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
AU2006230436B2 (en) 2005-03-31 2011-11-24 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
CA2606002A1 (en) * 2005-04-28 2006-11-02 Benitec Limited Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns
EP2395012B8 (en) 2005-11-02 2018-06-06 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
EP3067047A1 (en) 2005-12-08 2016-09-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
CA2633070C (en) 2005-12-19 2016-03-08 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20080275139A1 (en) * 2005-12-19 2008-11-06 Capsutech Ltd. Cyclodextrin-Containing Polymers and Uses Thereof
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
WO2007095342A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Stable corticosteroid mixtures
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
CN101970012A (en) * 2007-09-14 2011-02-09 日东电工株式会社 Drug carriers
EP2194068B1 (en) * 2007-09-28 2013-04-17 Nanodex INC. Cyclodextrin compound modified with folic acid, process for production thereof, drug delivery agent for targeting drug delivery system, pharmaceutical composition, and imaging agent
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
BRPI0911332A2 (en) 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc compositions and use of epas1 inhibitors
CA2721380A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
WO2010011895A1 (en) * 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
EP2401225B1 (en) 2009-02-26 2014-10-22 The Regents of The University of California A supramolecular approach for preparation of size controllable nanoparticles
EA201200617A1 (en) 2009-11-23 2012-11-30 Серулин Фарма Инк. Polymers on the basis of cyclodextrine for delivery of medicines
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
CA2802994A1 (en) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions and methods for treating inflammatory conditions
CN104818276A (en) 2010-07-08 2015-08-05 株式会社博纳克 Single-strand nucleic acid molecule for controlling gene expression
ES2527660T3 (en) 2010-08-03 2015-01-28 Bonac Corporation Single stranded RNA molecule that has an alicyclic skeleton that contains nitrogen
WO2012017208A1 (en) 2010-08-04 2012-02-09 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012061409A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
CA2859046C (en) 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
AU2013209452B2 (en) 2012-01-19 2015-11-05 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2780456A1 (en) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutic rna switches compositions and methods of use
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
CN110055247A (en) 2012-01-07 2019-07-26 株式会社博纳克 Single stranded nucleic acid molecule with amino acid backbone
JP2015505559A (en) * 2012-01-31 2015-02-23 セルリアン・ファーマ・インコーポレイテッド Cyclodextrin-based polymers for therapeutic agent delivery
EP2838653A4 (en) 2012-04-18 2015-11-25 Cerulean Pharma Inc Methods and systems for polymer precipitation and generation of particles
BR112014029010A2 (en) 2012-05-21 2017-06-27 Insmed Inc systems for treating pulmonary infections
MX2015006681A (en) 2012-11-29 2016-04-06 Insmed Inc Stabilized vancomycin formulations.
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
WO2015175539A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Engineering synthetic brain penetrating gene vectors
US9895385B2 (en) 2014-05-15 2018-02-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
CA2963271A1 (en) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
JP2018506525A (en) 2015-01-27 2018-03-08 ザ・ジョンズ・ホプキンス・ユニバーシティー A hypotonic hydrogel formulation for enhanced delivery of active agents across mucosal surfaces
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
WO2018169960A1 (en) 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32268E (en) * 1973-03-01 1986-10-21 Strategic Medical Research Corp. Therapeutic composition and method of therapeutically treating warm blooded animals therewith
JPS58167613A (en) * 1982-03-26 1983-10-03 Mitsubishi Petrochem Co Ltd Preparation of water-soluble cyclodextrin-containing polymer
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
JP2993967B2 (en) * 1987-06-17 1999-12-27 インスティテュート・フォー・チャイルド・ヘルス・リサーチ Cloning of mite allergen
US4774329A (en) 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US4941996A (en) 1987-10-19 1990-07-17 Minnesota Mining And Manufacturing Company Inclusion complexes providing second harmonic generation
HU203899B (en) * 1988-05-03 1991-10-28 Forte Fotokemiai Ipar Process for producing gelatine-cyclodextreine polymeres
US4902788A (en) 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
JPH03221505A (en) 1990-01-29 1991-09-30 Toppan Printing Co Ltd Synthesis of cyclodextrin polymer and production of cyclodextrin film
IT1241417B (en) 1990-03-06 1994-01-14 Vectorpharma Int Therapeutic compositions with controlled release of drugs supportatisu crosslinked polymers and coated with polymer films, and their preparation processodi
DE4009825A1 (en) 1990-03-27 1991-10-02 Consortium Elektrochem Ind Water-insoluble cyclodextrin polymers and process for their preparation
JPH0425505A (en) * 1990-05-21 1992-01-29 Toppan Printing Co Ltd Cyclodextrain polymer and production of cyclodextrin membrane
FR2665169A1 (en) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Cyclodextrin inclusion compounds containing phenolic antioxidants and their use in polymers
JPH04106101A (en) * 1990-08-27 1992-04-08 Showa Denko Kk Cyclodextrin polymer and its production
JPH0586103A (en) * 1990-10-01 1993-04-06 Toppan Printing Co Ltd Cyclodextrin polymer
US5208316A (en) 1990-10-01 1993-05-04 Toppan Printing Co., Ltd. Cyclodextrin polymer and cyclodextrin membrane prepared using said polymer
DE69127810D1 (en) * 1990-11-30 1997-11-06 Toppan Printing Co Ltd A process for producing a cyclodextrin derivative and polymer which contains cyclodextrin immobilized therein
EP0602149A1 (en) 1991-09-06 1994-06-22 Commonwealth Scientific And Industrial Research Organisation Composition and method for reducing cholesterol concentration
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IT1256134B (en) 1992-09-09 1995-11-29 Luigi Boltri Salts containing lipophilic neutron isotopes that can be activated and compositions containing them
EP0624166B1 (en) 1992-11-30 1997-04-16 Novartis AG Polymerizable carbohydrate esters, polymers made from such esters and the use of such polymers
TW328535B (en) 1993-07-02 1998-03-21 Novartis Ag Functional photoinitiators and their manufacture
TW307775B (en) 1994-02-15 1997-06-11 Novartis Erfind Verwalt Gmbh Unsaturated carbohydrate derivatives, polymers thereof and their use
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5776842A (en) 1994-06-23 1998-07-07 Cellresin Technologies, Llc Cellulosic web with a contaminant barrier or trap
JP3699141B2 (en) 1994-09-24 2005-09-28 伸彦 由井 Biomolecular assembly of biodegradable pharmaceutical polymer having supramolecular structure and preparation method thereof
JP3830198B2 (en) 1996-03-29 2006-10-04 東光薬品工業株式会社 Skin-permeable indomethacin external preparation using supramolecular structure polymer aggregate
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
CA2353552A1 (en) * 1998-12-04 2000-06-15 California Institute Of Technology Supramolecular complexes containing therapeutic agents
WO2000075162A1 (en) 1999-06-07 2000-12-14 Mirus Corporation A compound containing a labile disulfide bond
DK1102785T3 (en) 1999-06-07 2013-05-13 Arrowhead Res Corp Compositions for drug delivery using pH-sensitive molecules
WO2001037665A1 (en) 1999-11-29 2001-05-31 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules

Also Published As

Publication number Publication date
JP2002519482A (en) 2002-07-02
JP2011006695A (en) 2011-01-13
HU0105472A2 (en) 2002-05-29
EP1093469A1 (en) 2001-04-25
HU229473B1 (en) 2014-01-28
IL140552D0 (en) 2002-02-10
US6509323B1 (en) 2003-01-21
ES2285844T3 (en) 2007-11-16
CA2336390C (en) 2011-02-22
EP1764112A3 (en) 2007-05-23
EP1764112A2 (en) 2007-03-21
HU0105472A3 (en) 2003-03-28
DK1093469T3 (en) 2007-09-17
CN100365024C (en) 2008-01-30
JP4741729B2 (en) 2011-08-10
PT1093469E (en) 2007-07-16
ES2403416T3 (en) 2013-05-17
CN1308639A (en) 2001-08-15
AU763114C (en) 2004-05-27
DE69935982T2 (en) 2008-01-10
BR9911754B1 (en) 2010-07-13
MXPA01000206A (en) 2002-10-17
AU4830599A (en) 2000-01-24
WO2000001734A1 (en) 2000-01-13
DE69935982D1 (en) 2007-06-14
CA2336390A1 (en) 2000-01-13
EP1764112B1 (en) 2013-02-13
EP1093469B1 (en) 2007-05-02
DK1764112T3 (en) 2013-03-11
AU763114B2 (en) 2003-07-10
BR9911754A (en) 2001-11-06
IL140552A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
DE69829040D1 (en) Elektroplattierungschemie
DE69938178D1 (en) Bewegungsverfolgunssystem
DE69937850D1 (en) Hautablationslaser
DE69919529D1 (en) Lungevenenablationskatheter
DE69911008D1 (en) Gasturbinenkraftstoffeinspritzdüse
DE69942272D1 (en) Deranordnungen
DE69931517D1 (en) Gewebeeinkapselungsvorrichtung
DE69936443D1 (en) Bedienungspersoneingagabevorrichtung
DE69925401D1 (en) Tintenbehälternachfüllverfahren
DE69917956D1 (en) Tintenzuführsystemadapter
DE59914158D1 (en) Metallocenmonohalogenide
DE69916556D1 (en) Bohrhülsensysteme
DK0967684T3 (en) Bösningskontakt
DE69936806D1 (en) Spreizspektrumnachrichtenübertragungsverfahren
DE69937964D1 (en) Transportreagentien
DE69933567D1 (en) sigmidoskop
DE69937154D1 (en) keratotome
DE69931324D1 (en) Schrittfräsmethode
DK0965343T3 (en) Ziprasidonformuleringer
DE69940913D1 (en) ldautomat
DE69938834D1 (en) Gelierenen kältepackung
DE69904211T2 (en) Polyalcoxylated naphtopyrans
DE69911432D1 (en) abgasrückfürungseinrichtung
DE69933374D1 (en) operationsleucthtensteuerung
DE69808419D1 (en) merhzwecktaschenwerkzeug

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1093469

Country of ref document: EP